Study on the Protective Effects of Compound Blood-activating Soup on Bone Marrow Hematopoietic Cells in Acute Radiation Injured Mice

After irradiation with 8 Gy 60Coγ-ray,mice were immediaterly given intraperitoneal injection of 200 mg 100 % compound blood-activating soup twice a day. On the 3rd and 7th day, the P53 gene expression of bone marrow hematopoietic cells in Chinese drug group was found to be higher than that in normal group, and it was also significantly higher than that in control group. The expression level of GADD153 gene which was not expressed in normal group was much lower in Chinese drug group than that in control group. On the 7th day after irradiation, the P53 and GADD153 gene expression levels of splenic mononuclear cells were consistent with those of bone marrow hematopoietic cells both in Chinese drug group and control group. On the 3rd and 7th day, the bone marrow hematopoietic tissue volume in Chinese drug group was higher than that in control group, with no difference found between the two groups. While on the 14th day, the difference became significant (P＜0. 01). The results showed that commonly used blood-activating and stasis-eliminating drugs may strengthen .the viability of hematopoietic cells and promote the rehabilitation of hematopoiesis by inducing wt-P53 expression to block the bone marrow hematopoietic cells in G1 phase, during which DNA could be repaired.

Neurological complications of hematopoietic cell transplantation in children and adults

Hematopoietic cell transplantation（HCT） is widely performed for neoplastic and non-neoplastic diseases. HCT involves intravenous infusion of hematopoietic progenitor cells from human leukocyte antigen（HLA）-matched donor（allogeneic） or from the patient（autologous）. Before HCT, the patient is prepared with high dose chemotherapy and/or radiotherapy to destroy residual malignant cells and to reduce immunologic resistance. After HCT, chemotherapy is used to prevent graft rejection and graft versus host disease（Gv HD）. Neurological complications are related to the type of HCT, underlying disease, toxicity of the conditioning regimens, immunosuppression caused by conditioning regimens, vascular complications generated by thrombocytopenia and/or coagulopathy, Gv HD and inappropriate immune response. In this review, neurological complications are presented according to time of onset after HCT：（1） early complications（in the first month）-related to harvesting of stem cells, during conditioning（drug toxicity, posterior reversible encephalopathy syndrome）, related to pancytopenia,（2） intermediate phase complications（second to sixth month）-central nervous system infections caused by prolonged neutropenia and progressive multifocal leukoencephalopathy due to JC virus,（3） late phase complications（after sixth month）-neurological complications of Gv HD, second neoplasms and relapses of the original disease.

Higher plasma bilirubin predicts veno-occlusive disease in early childhood undergoing hematopoietic stem cell transplantation with cyclosporine

AIM: To analyze the association between plasma bilirubin levels and veno-occlusive disease(VOD) in non-adult patients undergoing hematopoietic stem cell transplantation(HSCT) during cyclosporine therapy.METHODS: A total of 123 patients taking cyclosporinewere evaluated using an electronic medical system at the Seoul National University Children's Hospital from the years 2004 through 2011. Patients were grouped by age and analyzed for incidence and type of adverse drug reactions(ADRs) including VOD. RESULTS: The HSCT patients were divided into three age groups: G#1 ≥ 18; 9 ≤ G#2 ≤ 17; and G#3 ≤ 8 years of age). The majority of transplant donor types were cord blood transplantations. Most prevalent ADRs represented acute graft-vs-host disease(a GVHD) and VOD. Although the incidences of a GVHD did not vary among the groups, the higher frequency ratios of VOD in G#3 suggested that an age of 8 or younger is a risk factor for developing VOD in HSCT patients. After cyclosporine therapy, the trough plasma concentrations of cyclosporine were lower in G#3 than in G#1, indicative of its increased clearance. Moreover, in G#3 only, a maximal total bilirubin level(BILmax) of ≥ 1.4 mg/d L correlated with VOD incidence after cyclosporine therapy. CONCLUSION: HSCT patients 8 years of age or younger are more at risk for developing VOD, diagnosed as hyperbilirubinemia, tender hepatomegaly, and ascites/weight gain after cyclosporine therapy, which may be represented by a criterion of plasma BILmax being ≥ 1.4 mg/d L, suggestive of more sensitive VOD indication in this age group.

Remission is not maintained over 2 years with hematopoietic stem cell transplantation for rheumatoid arthritis:A systematic review with meta-analysis

BACKGROUND Hematopoietic stem cell(HSC)transplantation(HSCT)is being accepted as a standard of care in various inflammatory diseases.The treatment of rheumatoid arthritis(RA)has been closely evolving with the understanding of disease pathogenesis.With the rising resistance to the traditional disease-modifying antirheumatic drugs and targeted biological therapy,researchers are in pursuit of other methods for disease management.Since the ultimate goal of the ideal treatment of RA is to restore immune tolerance,HSCT attracts much attention considering its reparative,paracrine,and anti-inflammatory effects.However,a systematic review of studies on HSCT in RA is lacking.AIM To investigate the role of HSCT in the management of RA.METHODS A detailed search of PubMed,Scopus,EMBASE,Cochrane,and the Web of Science databases was made to identify the relevant articles till September 2020 following Cochrane and PRISMA guidelines.We extracted data including the number of patients,source of hematopoietic stem cells,their mobilization and conditioning regimens,results,and complications from the eligible studies.Results were dichotomized into success(ACR 50/70)and failure(ACR 20)based on the improvement from baseline characteristics.The methodological quality of the included studies was also assessed.Analysis was performed using OpenMeta[Analysis]software.RESULTS We included 17 studies(1 randomized controlled trial,11 prospective,and 5 retrospective studies)with 233 patients for analysis.HSCT provided a significantly beneficial overall improvement in the clinical grades of ACR criteria(Z=11.309,P<0.001).However,the remission was noted only till 24 mo and later on the significance of the result was lost(Z=1.737,P=0.082).A less than 1%treatmentrelated mortality was noted from the included studies.No major drug-related toxicities were noted in any of the included studies.All patients who underwent allogeneic HSCT received immunosuppression in the conditioning regimen to counteract the graft-vs-host reaction which made them vulnerable to infections.It is noted that the source of hematopoietic stem cells did not play a role in altering the functional outcome and both autologous(Z=9.972,P<0.001)and allogenic(Z=6.978,P<0.001)sources produced significant improvement in the outcome compared to the pre-operative state despite having a significant heterogeneity among the studies reporting them(I2=99.4,P<0.001).CONCLUSION Although the available literature is encouraging towards the use of HSCT in refractory cases with significant improvement from baseline till 2 years,the inclusion of HSCT into the standard of care of RA needs further exploration.

The invivo study of myeloprotection by GST-π gene transfected human cord blood hematopoietic stem cells transplantation

Objective :To investigate the influence of GST πgenetransferintohumancord blood hematopoie ticstem cellson their drugres is tanceagains tanti tumordrugs invivo .Methods: GST πgenetran sfectionin to human cord blood CD 34+cells was carried outusing are trovirusvec torPLJ GST πwith the aido f fibronect in .Succes sfulgenetransfer was confirmed by invitrocolony assay and RT PCR .GST πgenetrans duced human cord blood CD34+cells were the nengrafted in to 4 week old total body irradiated NOD/Scid mice and carboplatin was intraperitoneally admin is tered sequentially at 4 weeks interval 4 week saftereng raftment.Results :Peripheral blood (PB) WBC was significantly higher in GST πmice than control mice after 2 course of car boplat in .Retroviral GST π expression in bone marrow hematopoietic progenitor cells of recipient mice was detected by RT PCR 16 weeks after Xenotransplantation .Conclusion :The transfection of GST π gene could confer ,to some extent ,resistance to cord blood stem cells against carboplatin in vivo .

In vitro study of the influence of GST-π gene transfer on drug-resistance of human cord blood CD34^+ cells

Objective:To investigate the influence of GST-π gene transfer on drug-resistance of human cord blood CD34 + cells.Methods:CD34 + cells were purified from cord blood from normal full-term pregnancy.Gene transduction into human cord blood CD34 + cells was carried out using GST-π gene containing retrovirus vector.The GST-π gene expression in transduced CD34 + cell was confirmed by RT-PCR.After confirmation of GST-π gene transfer,the transfected CD34 + cells were cultured by colony assay in the presence of carboplatin.Results:GST-π mRNA was detected in 30% of CFU-GM derived from GST-π gene transduced CD34 + cells.In vitro drug resistance test showed that the number of CFU-GM formed was significantly higher (2～3 fold) in GST-π gene transduced CD34 + cells than untransduced CD34 +cells.Conclusion:GST-π gene transfer can confer resistance to hematopoietic progenitors against carboplatin in vitro.

Liposome-mediated Functional Expression of Multiple Drug Resistance Gene in Human Bone Marrow CD34^+ Cells

Summary: The expression and functional activity of multiple drug resistance (MDR1) gene in human normal bone marrow CD34+ cells was observed. Human normal bone marrow CD34+ cells were enriched with magnetic cell sorting (MACS) system, and then liposome-mediated MDR1 gene was transferred into bone marrow CD34+ cells. Fluorescence-activated cell sorter was used to evaluate the expression and functional activity of P-glycoprotein (P-gp) encoded by MDR1 gene. It was found that the purity of bone marrow CD34+ cells was approximately (91±4.56) % and recovery rate was (72.3±2.36) % by MACS. The expression of P-gp in the transfected CD34+cells was obviously higher than that in non-transfected CD34+ cells. The amount of P-gp in non-transfected CD34+ cells was (11.2±2.2) %, but increased to (23.6±2.34) % 48 h after gene transfection (P<0.0l). The amount of P-gp was gradually decreased to the basic level one week later. The accumulation and extrusion assays showed that the overexpression of P-gp could efflux Rh-123 out of cells and there was low fluorescence within the transfected cells. The functional activity of P-gp could be inhibited by 10 μg/ml verapamil. It was suggested that the transient and highly effective expression and functional activity of P-gp could be obtained by liposome-mediated MRD1 transferring into human normal bone marrow CD34+ cells.

造血干细胞移植后并发阿萨希毛孢子菌血流感染1例并文献复习

目的:探讨血液恶性肿瘤患儿造血干细胞移植后发生阿萨希毛孢子菌血流感染的治疗药物选择。方法:分析1例造血干细胞移植后处于免疫抑制状态下血流感染阿萨希毛孢子菌的病例资料,结合既往文献,讨论并分析阿萨希毛孢子菌血流感染的药物治疗方案。结果:患儿在艾沙康唑治疗过程中发生了阿萨希毛孢子菌血流感染,调整为伏立康唑和两性霉素B脂质体联合治疗后,体温恢复正常,炎性指标好转,但由于患儿移植后出现了严重的肺部排斥反应,肺出血未能得到有效控制,最终放弃治疗。结论:血液恶性肿瘤患儿血流感染阿萨希毛孢子菌病死率高,在临床实践中应结合病情、体外药敏试验结果选择单药或联合治疗。阿萨希毛孢子菌应首选唑类药物,体外活性最强的是伏立康唑。两性霉素B抗真菌活性不充分,但与伏立康唑的联合治疗方案可能较伏立康唑单药或艾沙康唑单药治疗更具优势。

285例新型抗肿瘤药物不良反应分析

目的 研究新型抗肿瘤药物的药品不良反应(ADR)的发生规律及特点,为临床安全用药提供参考。方法 对某三甲综合医院2018年1月1日至2023年3月31日新型抗肿瘤药物致ADR共285例,对患者性别、年龄、超说明书用药、ADR累及系统-器官和临床表现、ADR分级与转归、关联性评价等进行回顾性统计分析。结果 285例ADR男性155例(54.39%),女性130例(45.61%),平均年龄(54.98±13.175)岁;临床表现426例次,累及系统-器官12个,最常见的为消化系统(44.13%)、血液及造血系统(19.01%);严重ADR 51例,新的ADR 6例。涉及新型抗肿瘤药物33种,其中国家医保谈判药物28种,共266例次,大分子单体克隆药物特别是免疫检查点抑制剂的ADR较多,ADR例数最多的是卡瑞利珠单抗(66例)。涉及超说明书用药118例,超说明书用药的ADR发生率为63.10%。结论 新型抗肿瘤药物相关的ADR可发生于各个年龄,累及多个器官-系统,严重ADR较多,新的ADR较少,超说明书用药相关ADR较多;建议通过多学科联合会诊(MDT)、超说明书备案等措施严格管理超说明书用药,加强用药教育和药学监护,提高用药的安全性和有效性。

西藏自治区人民医院实施国家重点监控药品干预成效分析

目的:评价西藏自治区人民医院对重点监控药品进行重点干预的成效,为优化重点监控药品干预策略、促进临床合理用药提供参考。方法:西藏自治区人民医院于2020年制订《西藏自治区人民医院重点监控药品管理规定》,建立《西藏自治区人民医院重点监控药品目录》,同时开展重点监控药品处方及医嘱专项点评、采取点评结果公示及绩效考核挂钩等目标性干预措施,对比西藏自治区人民医院2019年4月-2020年3月(干预前)与2020年4月-2021年3月(干预后第一年)及2021年4月-2022年3月(干预后第二年)重点监控药品临床使用数据变化,评价重点干预措施对该类药品的管理成效及临床使用的影响。结果:该院干预后第一年及第二年的重点监控药品销售金额分别为1427.01万元、1388.12万元,低于干预前的2004.29万元;干预后重点监控药品销售金额占药品总销售金额比例分别为8.33%、7.47%,低于干预前的10.11%。重点监控药品各品种的DDC普遍较高,患者的经济负担较重。结论:西藏自治区人民医院重点监控药品的干预取得了一定成效,但医院应在此基础上采取有力措施,提高重点监控药品合理使用,进一步减轻患者经济负担。

儿童费城染色体样急性淋巴细胞白血病的临床分析

目的:探讨具有治疗靶点的儿童费城染色体样急性淋巴细胞白血病(Ph-like ALL)的临床特点、分子学特征、治疗及预后。方法:2017年12月至2021年6月在苏州大学附属儿童医院初诊且具备靶向药物治疗靶点的儿童Ph-like ALL共27例,回顾性分析患儿年龄、性别、初诊时白细胞计数、遗传学特征、分子生物学改变、化疗方案、给予不同靶向药物、d 19微小残留病(MRD)、d 46 MRD、是否行造血干细胞移植(HSCT)等资料,归纳总结患儿的临床特征及治疗效果。采用Kaplan-Meier方法进行生存分析。结果:27例患儿均根据诱导缓解治疗过程中MRD水平调整化疗强度,10例在治疗过程中加用靶向药,3例患儿桥接HSCT,其中1例死亡,2例存活。24例未行HSCT患儿中,1例患儿出现复发,采用嵌合抗原受体T细胞(CAR-T)治疗后达完全缓解(CR)。27例患儿3年总生存率为(95.5±4.4)%,3年无复发生存率为(95.0±4.9)%,3年无事件生存率为(90.7±6.3)%。结论:基于MRD监测的危险度分层化疗可改善Ph-like ALL患儿预后,对化疗效果欠佳的患儿联合靶向药可尽快完全缓解,诱导缓解治疗过程中MRD持续阳性的Ph-like ALL患儿序贯CAR-T和HSCT能显著提高治疗效果。

地中海贫血患儿造血干细胞移植术后伏立康唑谷浓度及AUC的影响因素分析

目的分析地中海贫血患儿造血干细胞移植(HSCT)术后伏立康唑(VRZ)谷浓度(c_(min))和药时曲线下面积(AUC)的影响因素。方法选择2021年1月至2024年1月于我院接受HSCT并使用VRZ预防或治疗侵袭性真菌感染的地中海贫血患儿60例,采用高效液相色谱法测定VRZ的血药浓度并计算AUC;采用多元线性回归分析影响VRZ c_(min)、AUC的独立因素。结果共得到60例患儿的120例次VRZ c_(min),26例患儿的27例次VRZ AUC。VRZ c_(min)的中位浓度是0.31 mg/L,其中0.5~5 mg/L有46例次(38.33%),>5 mg/L有2例次(1.67%),<0.5 mg/L有72例次(60.00%);VRZ AUC的中位数是11.68 mg·h/L。患儿体重、HSCT术后时间、淋巴细胞计数以及是否合用苯妥英钠、他克莫司、环孢素对VRZ c_(min)有显著影响(P<0.05);淋巴细胞计数和是否合用苯妥英钠对VRZ AUC有显著影响(P<0.05)。结论患儿体重、HSCT术后时间、淋巴细胞计数以及是否合用苯妥英钠、他克莫司、环孢素是影响VRZ c_(min)的独立因素,淋巴细胞计数、是否合用苯妥英钠是影响VRZ AUC的独立因素。

应用失效模式与效应分析法提高药房盘点质量探索

目的:优化现代化门诊药房药品盘点过程以提升盘点质量。方法:通过文献检索、头脑风暴等方法绘制药品盘点流程图并收集每个子流程的潜在失效模式及失效原因,应用失效模式与效应分析法(Failure Mode and Effect Analysis,FMEA)对各失效模式发生的可能性、严重性和可侦测度进行评分及风险优先值(RPN)计算,量化并确定高风险失效模式,制定改进措施并实施,分析改善效果。结果:确定了盘点的3个主流程和12个子流程,以及各子流程相关的21项失效模式和38项失效原因,高风险因素共15项,制定针对性改进措施28项。干预改进后,各高风险失效模式RPN值均显著降低,其中最高的4项由392、288、280、280分别降至42、48、56、63,均处于相对低风险区域;干预管理前后复盘相符率由82.4%上涨至96.2%,盘存时长由180.2 min降至155.3 min。结论:FMEA法在药品盘点过程存在问题分析改进中的价值是肯定的,制定的各项改进措施,尤其是针对现代化药房自动化设备盘存模块的相关措施,以及低代码平台在智能化盘点中的应用等对于盘点质量的提升作用非常显著,值得借鉴并推广运用来提升药品经济和质量管理。

抗侵袭性真菌病治疗药物监测的研究进展

侵袭性真菌病(IFD)是一种深部感染性疾病,在血液系统恶性肿瘤患者中的发病率总体呈上升趋势。三唑类、多烯类、棘白菌素类抗真菌药物以及5-氟胞嘧啶和复方磺胺甲噁唑是临床治疗IFD的主要药物。对这些药物开展治疗药物监测有助于保证药物疗效、减少不良反应的发生。本文系统概述了以上5类药物的有效血药浓度范围,以及血药浓度与疗效和不良反应之间的相关性。固相萃取联合超高效液相色谱串联质谱技术在该研究领域是一种较有前景的检测方法。

急性髓系白血病维持治疗的研究进展

急性髓系白血病(AML)是成人最常见的急性白血病,通常预后不良。经过强化巩固治疗和造血干细胞移植后,复发仍然是导致治疗失败和死亡最常见的原因,也是治疗面临的最大挑战。已有研究证实包括去甲基化药物、靶向药物及免疫治疗等方案在内的维持治疗能够延长AML患者的缓解期,并改善生存。本文对当前具有代表性的维持治疗方案进行综述,并讨论目前存在的局限性与不足,以期为未来的研究及治疗提供思路。

伏立康唑及其代谢产物浓度监测在异基因造血干细胞移植患者中的应用研究

目的:探索移植后植入前(即移植后+1至+30 d)伏立康唑(voriconazole,VRCZ)及其代谢产物氮氧化物(voriconazole N-oxide,VNO)浓度监测在VRCZ用于异基因造血干细胞移植(allogeneic hematopoietic stem cell transplantation,allo-HSCT)患者防治真菌感染疗效和安全性中的应用价值。方法:分析VRCZ、VNO浓度及MR(CVNO/CVRCZ)的影响因素及在VRCZ防治真菌感染和发生肝肾损伤中的差异,并采用受试者工作特征曲线(ROC)对其进行分析(将曲线上约登指数最大一点对应值设定为临界值),确证其临界值。结果:影响VRCZ浓度(CVRCZ)、VNO浓度(CVNO)和MR的因素为:患者体重、VRCZ每日给药量及移植类型等(均P<0.05)。有效组CVRCZ和CVNO均明显高于无效组(P<0.001),MR则相反(P<0.001);肝、肾功能损伤组MR均明显低于正常组(P<0.05)。ROC显示,CVRCZ、CVNO和MR预测allo-HSCT患者移植后植入前VRCZ防治侵袭性真菌感染的临界值分别为0.95μg/ml、1.35μg/ml、1.645(AUC分别为0.9677、0.7634、0.9564)。CVRCZ和MR可以辅助提示患者肝[其临界值分别为0.65μg/ml、1.96(AUC分别为0.5971、0.6663)]、肾损伤[其临界值分别为0.95μg/ml、1.705(AUC分别为0.6039、0.6164)]。结论:同时监测VRCZ、VNO浓度及MR对预测allo-HSCT患者移植后植入前VRCZ防治侵袭性真菌感染具有重要价值,CVRCZ预测有效的准确性高于MR及CVNO;CVRCZ升高、MR降低会增加肝肾损伤的发生风险。

复发/难治性套细胞淋巴瘤治疗进展

套细胞淋巴瘤(MCL)是一种罕见的B细胞恶性肿瘤,占所有非霍奇金淋巴瘤(NHL)的3%~10%,常见于男性,中位发病年龄67岁,具有不可治愈、易复发和耐药等特点,复发后患者预后常较差,治疗选择有限。近年来,随着布鲁顿酪氨酸激酶抑制剂(BTKi)、B细胞淋巴瘤因子2抑制剂(BCL-2i)等为代表的靶向药物的应用,以及嵌合抗原受体T细胞(CAR-T)及异基因干细胞移植(allo-SCT)等疗法的进展,复发难治性(R/R)MCL患者的生存期明显延长。本文拟对目前R/R MCL的治疗进展进行综述。

源内裂解HPLC-MS/MS法快速测定造血干细胞移植患儿微量血浆中泊沙康唑和苯妥英浓度

目的建立一种源内裂解辅助调整线性范围的高效液相色谱串联质谱(HPLC-MS/MS)法快速测定造血干细胞移植(HSCT)患儿微量血浆中泊沙康唑和苯妥英的浓度。方法10μL血浆经甲醇沉淀蛋白,上清液经水稀释进样分析,内标分别为泊沙康唑-D4和苯妥英-D10;采用Kinetex EVO C18柱(30 mm×2.1 mm,2.6μm)分离,以水(A)和乙腈(B)为流动相,均含0.1%甲酸和2 mmol·L^(-1)乙酸铵,梯度洗脱,流速0.5 mL·min^(-1),柱温40℃,进样量2μL,运行时间2 min。电喷雾离子源正离子扫描下,采用多反应监测模式进行质谱分析。考察该方法的选择性、最低定量限和标准曲线、准确度和精密度、回收率、基质效应、稳定性、高脂效应和溶血效应。并用本法测定了我院10例HSCT患儿的泊沙康唑和苯妥英血药浓度。结果泊沙康唑、苯妥英及内标泊沙康唑-D4、苯妥英-D10的保留时间分别为1.05、0.98、1.05、0.97 min。泊沙康唑在0.1~12.8μg·mL^(-1)与峰面积呈良好的线性关系,最低定量限为0.1μg·mL^(-1);苯妥英在0.4~51.2μg·mL^(-1)与峰面积线性关系良好,最低定量限为0.4μg·mL^(-1);批内、批间准确度为92.65%~109.03%,批内、批间精密度的RSD均≤11.0%。两种药物的平均提取回收率均在86.21%~104.82%;内标归一化基质因子的RSD≤6.2%;高脂和2%溶血均不影响两种抗菌药物测定结果。样品的稳定性在试验条件下均良好。该法成功用于我院10例造血干细胞移植患儿血浆样本分析。结论本方法所需样本量小,简单快速、准确灵敏,可应用于泊沙康唑和苯妥英联合用药研究及治疗药物监测。

六味地黄汤对糖皮质激素肾阴虚模型免疫器官淋巴细胞凋亡的抑制作用(I)

为进一步探讨肾阴虚证在免疫学上的实质 ,将 30只Wister大鼠分为正常对照组、模型组、六味地黄汤组 3组 ,采用糖皮质激素肾阴虚大鼠模型以原位末端标记法标记凋亡细胞 ,观测了六味地黄汤对胸腺淋巴细胞凋亡的影响。结果显示 :模型组淋巴细胞凋亡增多 ,且多在胸腺皮质部 ,凋亡细胞计数模型组显著高于正常对照组 (P <0 .0 1) ;六味地黄汤组淋巴细胞凋亡较模型组明显减少 ,凋亡细胞计数六味地黄汤组低于模型组 (P <0 .0 1)。提示六味地黄汤能够抑制糖皮质激素诱导的胸腺淋巴细胞凋亡。反证了肾阴虚证存在胸腺淋巴细胞凋亡的情况 。

巴戟素对衰老大鼠空间学习记忆力的改善作用

用D -半乳糖化的方法制备大鼠衰老模型 ,通过Morris水迷宫测试 ,观察巴戟素对衰老大鼠空间学习记忆力的影响 ;应用海马脑片灌流技术 ,观察巴戟素对海马突触长时程增强 (LTP)的影响。结果显示 ,巴戟素能使衰老大鼠逃避潜伏期缩短 ;原平台象限游泳时间和 4 0cm环内游泳时间明显延长 ;原平台象限游泳路径百分比增加。还可显著增强海马脑片的LTP效应 ,并呈一定的量效关系。提示巴戟素可提高衰老大鼠的空间学习、记忆能力 。